Trial reportPediatric blood & cancer2015
Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
Trial report in Pediatric blood & cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.Scientific reports · 2018Pooled it
- A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.Blood advances · 2023Trial
- Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura.International journal of hematology · 2017Trial
- Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.BMC veterinary research · 2016Trial
- Management and outcomes of refractory immune thrombocytopenia in pediatric patients: A retrospective analysis from Ospedale Pediatrico Bambino Gesù.Annals of hematology · 2025Article
- Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology.Blood transfusion = Trasfusione del sangue · 2024Article
- Application of recombinant human thrombopoietin in pregnant women with immune thrombocytopenia: a single-center experience of four patients and literature review.The Journal of international medical research · 2023Review
- Advances in management of pediatric chronic immune thrombocytopenia: a narrative review.Journal of Yeungnam medical science · 2023Article
- Romiplostim use in pregnant women with immune thrombocytopenia.American journal of hematology · 2023Article
- Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry.Blood advances · 2021Article
- Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.Annals of hematology · 2021Review
- Article
- A Review of Romiplostim Mechanism of Action and Clinical Applicability.Drug design, development and therapy · 2021Review
- The role of romiplostim for pediatric patients with immune thrombocytopenia.Therapeutic advances in hematology · 2020Review
- Updated international consensus report on the investigation and management of primary immune thrombocytopenia.Blood advances · 2019Article
- Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.Haematologica · 2019Article
- Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.Blood advances · 2019Review
- Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.American journal of hematology · 2018Observational
- Management of newly diagnosed immune thrombocytopenia: can we change outcomes?Hematology. American Society of Hematology. Education Program · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment of chronic severe pediatric ITP is not well studied. In a phase 1/2 12-16-week study, 15/17 romiplostim-treated patients achieved platelet counts ≥50 × 10 PROCEDURE: Patients received weekly subcutaneous romiplostim, adjusted by 1 µg/kg/week to maintain platelet counts (50-200 × 10
resultsAt baseline, patients were median age 10.0 years; median ITP duration 2.4 years; median platelet count 13 × 10
conclusionsLong-term romiplostim treatment in this small cohort increased and maintained platelet counts for over 4 years in children with ITP with good tolerability and without significant toxicity. Pediatr Blood Cancer 2015;62:208-213. © 2014. The Authors. Pediatr Blood & Cancer published by Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.